BiotechnologyBiotechnology

Tax credits, specific project funding and deep-pocketed syndicates hit the radar as the biotech industry scrapes around for money.

Supreme Court Rulings and patent reform are making it harder to defend patents in the US – and biotechs are falling back on trade secrets to protect their IP.

Record venture capital and heated deal environment propelled biotechnology industry forward in 2007, says Ernst & Young’s biotech report for last year.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.